# Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

> **NCT05694936** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Australasian Gastro-Intestinal Trials Group** · enrollment: 38 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Sodium Valproate
- **DRUG:** Panitumumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05694936
- **Lead sponsor:** Australasian Gastro-Intestinal Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-23
- **Primary completion:** 2026-01-21
- **Final completion:** 2027-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05694936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05694936, "Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05694936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*